Thomas A. Singleton*, HyunJune Jun, Prashant S. Deore, Carl Estrada, Bren Jordan P. Atienza, Julie Delecueillerie, Mohamed E. El-Zaria, Afaf R. Genady, En Zhao, Simon Edelmann, Darcy Burley, Luis-Rafael Silva, Yusra M. Marfatia, Ayman A. Ibrahim, Patrick L. DeRoy, Alexandre Larivée, Anton A. Toutov, Christopher M. Waldmann*, Saman Sadeghi*, Jean-Philip Lumb* and Alexey Kostikov*,
{"title":"18f标记放射性药物用杂芳香氟化硅受体的研制。","authors":"Thomas A. Singleton*, HyunJune Jun, Prashant S. Deore, Carl Estrada, Bren Jordan P. Atienza, Julie Delecueillerie, Mohamed E. El-Zaria, Afaf R. Genady, En Zhao, Simon Edelmann, Darcy Burley, Luis-Rafael Silva, Yusra M. Marfatia, Ayman A. Ibrahim, Patrick L. DeRoy, Alexandre Larivée, Anton A. Toutov, Christopher M. Waldmann*, Saman Sadeghi*, Jean-Philip Lumb* and Alexey Kostikov*, ","doi":"10.1021/acs.jmedchem.5c01087","DOIUrl":null,"url":null,"abstract":"<p >Silicon Fluoride Acceptors (SiFAs) enable <sup>18</sup>F-labeling of complex peptides via isotope exchange under exceptionally mild conditions. SiFA radiopharmaceuticals have been clinically validated for diagnosing and treating cancers as tracers for positron emission tomography (PET) and radiotwin theranostics. Despite these advances, conventional phenyl SiFAs (PhSiFAs) require complex substrate engineering to mask their lipophilicity, which complicates the design of new tracers. Here, we report a new and diverse class of heteroaromatic SiFA derivatives (HetSiFAs) that are significantly less lipophilic than classical PhSiFAs. We show that HetSiFAs retain suitable stability without compromising labeling kinetics. We highlight the performance of a pyrazole-HetSiFA for rapid and efficient <sup>18</sup>F-labeling within a model TATE-peptide and show that the resulting PET tracer clears through the kidneys with minimal defluorination in mice. Novel radiopharmaceuticals incorporating HetSiFAs can capitalize on the improved and flexible pharmacokinetic parameters and excellent <sup>18</sup>F-fluorination efficiency offered by these scaffolds.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 15","pages":"16114–16137"},"PeriodicalIF":6.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of Heteroaromatic Silicon Fluoride Acceptors (HetSiFAs) for 18F-Labeled Radiopharmaceuticals\",\"authors\":\"Thomas A. Singleton*, HyunJune Jun, Prashant S. Deore, Carl Estrada, Bren Jordan P. Atienza, Julie Delecueillerie, Mohamed E. El-Zaria, Afaf R. Genady, En Zhao, Simon Edelmann, Darcy Burley, Luis-Rafael Silva, Yusra M. Marfatia, Ayman A. Ibrahim, Patrick L. DeRoy, Alexandre Larivée, Anton A. Toutov, Christopher M. Waldmann*, Saman Sadeghi*, Jean-Philip Lumb* and Alexey Kostikov*, \",\"doi\":\"10.1021/acs.jmedchem.5c01087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Silicon Fluoride Acceptors (SiFAs) enable <sup>18</sup>F-labeling of complex peptides via isotope exchange under exceptionally mild conditions. SiFA radiopharmaceuticals have been clinically validated for diagnosing and treating cancers as tracers for positron emission tomography (PET) and radiotwin theranostics. Despite these advances, conventional phenyl SiFAs (PhSiFAs) require complex substrate engineering to mask their lipophilicity, which complicates the design of new tracers. Here, we report a new and diverse class of heteroaromatic SiFA derivatives (HetSiFAs) that are significantly less lipophilic than classical PhSiFAs. We show that HetSiFAs retain suitable stability without compromising labeling kinetics. We highlight the performance of a pyrazole-HetSiFA for rapid and efficient <sup>18</sup>F-labeling within a model TATE-peptide and show that the resulting PET tracer clears through the kidneys with minimal defluorination in mice. Novel radiopharmaceuticals incorporating HetSiFAs can capitalize on the improved and flexible pharmacokinetic parameters and excellent <sup>18</sup>F-fluorination efficiency offered by these scaffolds.</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 15\",\"pages\":\"16114–16137\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01087\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01087","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Development of Heteroaromatic Silicon Fluoride Acceptors (HetSiFAs) for 18F-Labeled Radiopharmaceuticals
Silicon Fluoride Acceptors (SiFAs) enable 18F-labeling of complex peptides via isotope exchange under exceptionally mild conditions. SiFA radiopharmaceuticals have been clinically validated for diagnosing and treating cancers as tracers for positron emission tomography (PET) and radiotwin theranostics. Despite these advances, conventional phenyl SiFAs (PhSiFAs) require complex substrate engineering to mask their lipophilicity, which complicates the design of new tracers. Here, we report a new and diverse class of heteroaromatic SiFA derivatives (HetSiFAs) that are significantly less lipophilic than classical PhSiFAs. We show that HetSiFAs retain suitable stability without compromising labeling kinetics. We highlight the performance of a pyrazole-HetSiFA for rapid and efficient 18F-labeling within a model TATE-peptide and show that the resulting PET tracer clears through the kidneys with minimal defluorination in mice. Novel radiopharmaceuticals incorporating HetSiFAs can capitalize on the improved and flexible pharmacokinetic parameters and excellent 18F-fluorination efficiency offered by these scaffolds.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.